Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis (JAKIGREAT)

University Hospital, Lille

Status: Unknown

Conditions: Dermatitis, Atopic

Study type: Observational

Funder types: Other

Identifiers

NCT04761978

NI_2021_01

Details and patient eligibility

About

The aim is to assess effectiveness (EASI, SCORAD, IGA, DLQI, pruritus, sleep loss) and safety (clinical and biological adverse events) of JAK inhibitors in adults with moderate-to-severe atopic dermatitis in a real-life French multicenter retrospective cohort

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adults
• moderate to severe atopic dermatitis
• treated by JAK inhibitors between december 2020 and september 2021
• inefficiency, loss of efficiency or contra-indication of previous systemic agent, DUPILUMAB or phototherapy
• ineligibility to French ongoing clinical trials

Exclusion criteria

• Children
• mild atopic dermatitis
• eligibility to CICLOSPORINE, METHOTREXATE, DUPILUMAB, phototherapy
• eligibility to French ongoing clinical trials
• patients' opposition for the use of their records
• follow up <3 months